The Potential Benefits of Electronic Cigarettes: A Long-term Study

Sep.05.2022
The Potential Benefits of Electronic Cigarettes: A Long-term Study
A long-term experiment shows e-cigarette usage can reduce the harm of smoking compared to traditional cigarettes.

A long-term experiment involving hundreds of smokers was conducted, in which some continued to smoke, while others switched completely to e-cigarettes, and some quit nicotine altogether. Analysis of biological markers for potential harm indicated that completely switching to e-cigarettes can reduce the harm associated with smoking.


In 1798, Dr. Benjamin Rush was one of the earliest people to suggest that smoking could lead to cancer. By the 1920s, over a thousand cases of lung cancer had been reported. Meanwhile, inventors began looking for ways to reduce the risks of tobacco. In 1927, American Joseph Robinson patented a device that produced electronic vapor and proposed the safe inhalation of vapors containing medicinal compounds without being burned. This idea remained on paper.


The modern e-cigarette did not appear until 2003, when it was developed by Chinese pharmacist Hon Lik. Since then, its popularity has gradually increased. Today, lung cancer is the second most common cancer in the world, with smoking being the main cause of its development (in 85% of cases). In Russia, the incidence and mortality rates of lung cancer also rank second, causing 27,000 deaths each year.


Since 2019, the number of smokers in Russia has been declining gradually. According to VTsIOM, approximately one-third of the population in urban areas smoke, with the majority of them smoking more than a pack a day using traditional methods such as cigarettes, cigars, roll-your-own and hookah. However, there is a rapid increase in the popularity of e-cigarettes.


Electronic cigarettes entered Europe, the United States, and Russia around 2007. At that time, there were no studies on the effects of these new products on the body, and as a result, health organizations and doctors were unsure how to regulate their circulation and provide advice to people. Today, the global electronic cigarette market is valued at over $18 billion. Analysis shows that smoking not only wastes money but also has a negative impact on health. Smokers have a death rate over three times higher than non-smokers after the age of 65.


Alternative products to traditional cigarettes are becoming increasingly popular worldwide. Many have successfully quit smoking with their help. For those who are not ready or unable to quit smoking entirely, electronic cigarettes can reduce the amount of toxins inhaled. Fortunately, over the past 20 years, there have been enough medical observations and scientific studies to conclude that high-quality, verified electronic cigarettes can reduce harm to health and help overcome addiction.


One method of monitoring the effects of smoking on the body is to track exposure biomarkers (BoE) and potential harm (BoPH) associated with oxidative stress, cancer, cardiovascular disease, and respiratory illness.


A new study on biomarkers has indicated that completely switching from traditional cigarettes to alternative smoking products can significantly reduce the harm caused by smoking.


In the UK, scientists have decided to examine the changes in biomarkers of individuals who have quit smoking or switched to e-cigarettes completely over a few months. The transition to heating systems is equivalent to quitting smoking completely for some biomarkers. The results have been published in the peer-reviewed medical journal, "Internal Medicine and Emergency Medicine Journal".


The study involved adults aged 23 to 55 who had been smoking for at least 5 years and were smoking between 10-30 non-menthol cigarettes per day at the start of the study. They were all healthy. Participants who wished to continue smoking were randomly divided into two groups: one group continued to smoke regular cigarettes, while the second group was given electronic cigarettes. At the time of publication, 59 people continued to smoke, 127 people switched to electronic cigarettes, 109 people stopped smoking altogether, and 37 people were in the control group. To monitor compliance, participants were tested for CEVal biomarkers.


It is worth noting that participants who switched to e-cigarettes prior to the experiment had slightly higher consumption rates compared to traditional cigarette users (with one e-cigarette deemed equivalent to one cigarette) and those who continued smoking. However, this consumption rate remained stable throughout all six months of the study. The results indicate that switching to e-cigarettes led to statistically significant changes in biological markers, with some even approaching data from the group who quit smoking altogether. Canadian scientists have discovered that smokers and those with chronic obstructive pulmonary disease show increased entry of SARS-CoV-2 into their epithelial cells.


Biomarkers for oxidative stress in the body (8-Epi-PGF2α Type III) were significantly reduced, and white blood cell count decreased (indicating a presence of inflammation). At the same time, indicators of lung and vascular health improved, as did the level of high-density lipoprotein cholesterol, which suggests a lower risk for cardiovascular disease. Most importantly, those who switched to e-cigarettes saw a decrease of about half in NNAL levels (a lung cancer risk indicator) to 115.7 ng/day. Of course, the decrease was even greater in those who quit smoking entirely, going from smokers' levels (221.94 ng/day) to four times less (59.09 ng/day). However, in order to reach the levels of those who never smoked, the decrease must be 20 times less (to 11.54 ng/day).


It’s important to remember that there are different alternatives to traditional smoking, and they are all quite different from each other. Electronic cigarettes or e-cigarettes use a special liquid that produces thick vapor. The primary ingredients in this liquid are glycerin or propylene glycol, which are compounds used in smoke machines. Studies have shown that these ingredients do not cause lung inflammation, but they do cause dryness. The e-liquid used in e-cigarettes can contain nicotine (at varying concentrations) or it can be nicotine-free.


Nicotine has been proven to be addictive, but the main harm comes from other toxic compounds formed during the combustion of tobacco - there are about 6,000 of them. Some scientists believe that these compounds increase the risk of addiction to nicotine.


Disclaimer: 1. The content of this article is compiled from third-party information and is only for industry exchange and learning. 2. This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity and accuracy of the content of the article. The compilation of this article is only for industry exchange and research. 3. Due to the limited level of compilation, the compiled article may not express the same meaning as the original article, please refer to the original article for accuracy. 4. For any domestic, Hong Kong, Macao, Taiwan, or foreign expressions and positions, 2FIRSTS is fully in line with the Chinese government. 5. The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
American Vapor Manufacturers (AVM) and Altria subsidiaries Helix Innovations and NJOY filed separate motions on October 7, 2026, seeking to intervene on the FDA's side in a lawsuit challenging its enforcement guidance for certain e-cigarette and nicotine pouch products with pending premarket tobacco product applications (PMTAs). Seven public health and tobacco-control organizations, including the Campaign for Tobacco-Free Kids, sued the agency in July to overturn the policy. AVM argues that vacating the guidance could disrupt orders, inventory, retail distribution and investments in regulatory submissions.
Regulations
Oct.09
China Tobacco Supply-Chain Leader Huabao’s Three-Way Transformation Takes Hold as Overseas Revenue Jumps 216%, Non-Flavor Businesses Reach 42.2% and the Company Expands Into Global Next-Generation Tobacco Supply Chains
China Tobacco Supply-Chain Leader Huabao’s Three-Way Transformation Takes Hold as Overseas Revenue Jumps 216%, Non-Flavor Businesses Reach 42.2% and the Company Expands Into Global Next-Generation Tobacco Supply Chains
Huabao’s H1 2026 results show the company advancing across three connected fronts: international expansion, entry into next-generation tobacco supply chains and diversification beyond its traditional tobacco-related base. Overseas revenue rose 216.08% to CNY 96.02 million, while non-flavor businesses reached 42.2% of total revenue. Huabao also said it had entered the supply chains of leading global tobacco customers, as its nutrition, food ingredient, fragrance and personal-care businesses gained ground in Europe, Southeast Asia, Australia and New Zealand. However, adjusted net profit increased only 2.78%, and next-generation tobacco revenue was not separately disclosed, showing that the transformation is reshaping revenue and customer exposure but has yet to translate fully into underlying earnings.
Aug.28
Product | JNR Launches Crown Shisha 100K for International Wholesale, Pairing 58ml Capacity With Triple-Mesh DTL Design
Product | JNR Launches Crown Shisha 100K for International Wholesale, Pairing 58ml Capacity With Triple-Mesh DTL Design
JNR released the Crown Shisha 100K on August 14, 2026, positioning the ultra-high-capacity disposable around a direct-to-lung (DTL) e-shisha experience. The device combines a 58ml e-liquid capacity, triple 1.0Ω mesh coils and a 1,300mAh rechargeable battery, with JNR claiming up to 100,000 puffs. Adjustable airflow, battery and e-liquid status displays, a leather-style exterior and a shisha-inspired sound effect further differentiate the product. JNR is currently promoting the device through international wholesale and distribution channels, while a specific first retail market has not been disclosed.
Aug.31
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Three R.J. Reynolds companies are seeking to intervene in a lawsuit filed by Altria subsidiaries Helix Innovations and NJOY challenging the FDA's 2021 PMTA final rule. The companies dispute how the agency uses Acceptance and Filing reviews and completeness determinations to establish when the Tobacco Control Act's 180-day decision period begins. Reynolds has also linked prolonged PMTA reviews to competition from unauthorized vaping products. The FDA, meanwhile, has been accelerating reviews and reducing its backlog.
Sep.14
Huabao International Buys Indonesian HNB Manufacturer for RMB 90 Million, Adding OEM/ODM Capacity
Huabao International Buys Indonesian HNB Manufacturer for RMB 90 Million, Adding OEM/ODM Capacity
Huabao International Holdings Limited will acquire 100% of PT Broad Far Indonesia through two wholly owned subsidiaries for approximately RMB 90 million. The Indonesian company manufactures and sells heat-not-burn tobacco sticks and provides OEM/ODM services. The sellers are part of a related-party group controlled by Huabao International Chair and controlling shareholder Zhu Linyao. PT Broad Far Indonesia generated $4.37 million in revenue and $177,000 in profit after tax in the first half of 2026, while net assets stood at about $326,000 at June-end. An independent valuer assessed the company’s equity at approximately RMB 93.06 million. Following completion, the HNB manufacturing operation will be consolidated into Huabao International.
News
Sep.29 by 2Firsts Perspectives
Product | Philip Morris Japan Launches Ginza-Exclusive IQOS ILUMA i PRIME, Limited to 1,814 Units at First Global Flagship
Product | Philip Morris Japan Launches Ginza-Exclusive IQOS ILUMA i PRIME, Limited to 1,814 Units at First Global Flagship
Philip Morris Japan (PMJ) launched the IQOS ILUMA i PRIME Ginza Limited Model Set in Tokyo on September 4, 2026, alongside the opening of IQOS Flagship Ginza, the brand’s first global flagship store. The Oasis Blue edition is limited to 1,814 individually numbered units, with the figure derived from the store’s address at Ginza 1-8-14. The set also includes two Yamanaka-nuri glasses and special packaging, priced at JPY 11,980 and sold exclusively at the Ginza flagship.
Sep.07